https://doi.org/10.55788/a556ceef
An international project has established the feasibility of ambulatory seizure forecasting with multiple minimally-invasive devices, from medical-grade/research-grade devices to fitness trackers, using seizure cycles and subcutaneous EEG. Epileptic seizure cycles are common, measurable with different modalities, and strong predictors of future seizures.
From a patient’s perspective, one of the most difficult and debilitating aspects of epilepsy is seizure unpredictability. “Because of the potential harm that seizures can inflict onto patients or others, including sudden death, patients live in a state of perpetual uncertainty,” said lead author of the project Dr Pedro Faro Viana (King’s College London, UK) [1]. Forecasting of seizures with an implantable intracranial EEG (iEEG) device is not appropriate for all patients and in any case minimally- or non-invasive EEG recording systems would be preferable.
Patients with drug-resistant epilepsy were enrolled in a prospective, multicentre, observational cohort for ultra long-term (>8 months) monitoring with an electronic diary, a wearable device, and ambulatory EEG monitoring [1]. Wearable devices employed were the Empatica E4, the smaller and more stylish Embrace 2 (if the Empatica E4 was refused), and the Fitbit Charge 3 or Fitbit Inspire. Ambulatory EEG devices included were NeuroPace RNS, Medtronic RC+S, UNEEG 24/7 SubQ, and EpiMinder.
A total of 40 participants had recorded >11,400 days (31.2 years) of ambulatory data, including 1,712 EEG seizures. Nine patients terminated this observational study prematurely. These were some of the results:
- The Empatica E4 and NeuroPace RNS showed that seizures occur in cycles. Heart rate circadian and multi-day cycles were significantly phase-locked with the likelihood of self-reported seizures [2].
- The Empatica E4 plus a seizure forecasting system with a long short-term memory (LSTM) recurrent neural network (RNN) algorithm predicted seizures significantly better than chance in 5/6 patients, with a mean area under the curve (AUC) of 0.80 [3].
- The wrist-worn Fitbit plus LSTM RNN also predicted seizures significantly better than chance in 5/6 patients, with an AUC of 0.74 (hourly forecasts) and 0.66 (daily forecasts) [4].
- The UNEEG 24/7 subscalp achieved significant forecasting performance in 3–5 out of 6 patients, with overall mean AUC of 0.65–0.74 [5].
The main study limitations were a small cohort, some cases of device deficiency, poor adherence and/or incomplete data, and retrospective or (pseudo-) prospective forecasting.
- Viana P, et al. Seizure forecasting with non-invasive and minimally-invasive mobile devices – Epilepsy Foundation My Seizure Gauge study. OPR-078, EAN 2022, 25–28 April, Vienna, Austria.
- Gregg NM, et al. Under review.
- Nasseri M, et al. Sci Rep. 2021;11(1):21935.
- Stirling RE, et al. Front Neurol. 2021;12:713794.
- Viana PF, et al. Epilepsia. Apr 8 2022. DOI: 10.1111/epi.17252.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Real-world efficacy of cenobamate in focal-onset seizures Next Article
Large impact of COVID-19 on dementia diagnosis and care »
Table of Contents: EAN 2022
Featured articles
Letter from the Editor
Overarching Theme
Migraine
Targeting cortical activation by transcranial magnetic stimulation
Erenumab more than doubles plasma CGRP levels
Over a third of patients responds late to CGRP antibodies
Multiple Sclerosis
When to start, switch, and stop MS therapy: Real-world evidence counts
Updated EAN-ECTRIMS guideline on pharmacological MS treatment
Gut microbiota composition associated with disability worsening
Teriflunomide in children with MS: final results of TERIKIDS
Estimating brain age in MS: machine learning versus deep learning
Ofatumumab improves cognitive processing speed
Parkinson’s Disease
Intestinal alterations in patients with Parkinson’s disease
Gene variants impact survival in monogenic Parkinson’s disease
Cerebrovascular Disease and Stroke
Most acute stroke patients have undiagnosed risk factors
Absence of Susceptibility Vessel Sign points to malignancy in stroke patients
Acute stroke management: from time window to tissue window?
Epilepsy
Seizure forecasting with non- and minimally-invasive devices
Real-world efficacy of cenobamate in focal-onset seizures
Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy
COVID-19
COVID-19 elevates risk of neurodegenerative disorders
More headaches in adolescents during COVID-19 pandemic
AstraZeneca vaccination and risk of cerebral venous sinus thrombosis
Large impact of COVID-19 on dementia diagnosis and care
Miscellaneous
Tau autoimmunity associated with systemic disease
Long-term effects of avalglucosidase alfa in late-onset Pompe disease
European survey of patient satisfaction in the treatment of cancer-related neuropathic pain
Related Articles
Tau autoimmunity associated with systemic disease
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy